Nivolumab Plus Ipilimumab (Opdivo Plus Yervoy)

Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec. This review assesses nivolumab (Opdivo), 40 mg/4 mL (10 mg/mL) and 100 mg/10 mL (10 mg/mL), and ipilimumab (Yervoy), 50 mg/10 mL (5 mg/mL) and 200 mg/40 mL (5 mg/mL). Indication: Opdivo (nivolumab), in combination with ipilimumab is indicated for the first-line treatment of adult patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer.